United Therapeutics Corp. COO Roger Jeffs Sells 10,000 Shares (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) COO Roger Jeffs unloaded 10,000 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $85.48, for a total transaction of $854,800.00. Following the sale, the chief operating officer now directly owns 19,760 shares in the company, valued at approximately $1,689,085. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.96% on Friday, hitting $85.48. 547,741 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $85.92. The stock has a 50-day moving average of $76.23 and a 200-day moving average of $68.75. The company has a market cap of $4.267 billion and a price-to-earnings ratio of 14.60.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis.
A number of analysts have recently weighed in on UTHR shares. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has issued a buy rating to the company’s stock. United Therapeutics Corp. presently has a consensus rating of “Hold” and a consensus target price of $64.20.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.